Preferred Label : Alagille syndrome 1;
Symbol : ALGS1;
CISMeF acronym : AHD; ALGS; ALGS1; AWS;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Alagille-watson syndrome; Cholestasis with peripheral pulmonary stenosis; Hepatic ductular hypoplasia, syndromatic; Arteriohepatic dysplasia; AWS; AHD; ALGS; Alagille syndrome;
Description : Alagille syndrome is an autosomal dominant disorder that traditionally has been defined
by a paucity of intrahepatic bile ducts, in association with 5 main clinical abnormalities:
cholestasis, cardiac disease, skeletal abnormalities, ocular abnormalities, and a
characteristic facial phenotype (Li et al., 1997). Cholestasis is a direct consequence
of the paucity of bile ducts. About 39% of patients also have renal involvement, mainly
renal dysplasia (Kamath et al., 2012). Turnpenny and Ellard (2012) reviewed the clinical
features, diagnosis, pathogenesis, and genetics of Alagille syndrome. - Genetic Heterogeneity
of Alagille Syndrome Another form of Alagille syndrome (ALGS2; 610205) is caused by
mutation in the NOTCH2 gene (600275).;
Inheritance : Autosomal dominant;
Molecular basis : Caused by mutation in the jagged 1 gene (JAG1, 601920.0001);
Neoplasia : Hepatocellular carcinoma; Papillary thyroid carcinoma;
Laboratory abnormalities : Increased conjugated bilirubin; Hypercholesterolemia; Hypertriglyceridemia; Elevated transaminases;
Prefixed ID : #118450;
Origin ID : 118450;
UMLS CUI : C1956125;
- Automatic exact mappings (from CISMeF team)
- Broader ORDO disease(s)
- Currated CISMeF NLP mapping
- DO Cross reference
- False automatic mappings
- Genes related to phenotype
- HPO term(s)
- ORDO concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to NTBT